Skip to content
News Radio KOTA
    • Sample Page
Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting

Author: Biolojic Design

Posted Date:

April 17, 2026
  • Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting

    Biolojic Design
    April 17, 2026
  • Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)

    Biolojic Design
    March 25, 2026